ADVANCED RESEARCH IN GASTROENTEROLOGY & HEPATOLOGY JUNIPER PUBLISHERS Authored by Juandy Jo Opinion We are witnessing the rapid advancement of immunotherapy, in particular of adoptive cellular therapy, against cancers over the past decade. Currently, adoptive cellular therapy comprises of three classes, i.e., by using tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR)-, or T-cell receptor (TCR)-engineered T cells [ 1 ]. While TILs are obtained through the isolation from tumor mass, the latter two methods obtain T cells through the genetic engineering. The CAR- and TCR- engineered T cells are gaining popularity due to, partly, their ability to evade the immune suppression, frequently observed on tumor-specific T cells. These gene-modified T cells would permit the immune system to confer an adequate immuneresponse, which is naturally may not present at all [ 1 ]. Several published articles on the distinction between the ...
